Search clinical trials for: TH-302 combination with pemetrexed

Total 855 results

Threshold Pharmaceuticals
EMD Serono

Terminated

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Germany, Spain, Poland, Greece, Czechia, Hungary, Italy, Romania, Russian Federation
Threshold Pharmaceuticals

Terminated

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Metastatic Melanoma

United States, Canada
Sarcoma Alliance for Research through Collaboration
Threshold Pharmaceuticals

No longer available

SARC021C: A Continuation Study of TH-CR-406/SARC021

Soft Tissue Sarcoma
Threshold Pharmaceuticals

Unknown

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Solid Tumors

United States
Threshold Pharmaceuticals

Completed

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Hypoxia | Tumors

United States
Threshold Pharmaceuticals

Completed

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced Myelofibrosis

United States
Seoul National University Hospital
Threshold Pharmaceuticals

Completed

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Herbert Hurwitz, MD
GlaxoSmithKline; National Comprehensive Cancer Network; Threshold Pharmaceuticals

Completed

Dose Escalation Study of Pazopanib Plus TH-302 (PATH)

Solid Tumors

United States
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Completed

A Phase 1 TH-302 Mass Balance Trial

Solid Tumor

Germany
Threshold Pharmaceuticals

Unknown

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Threshold Pharmaceuticals

Completed

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Threshold Pharmaceuticals

Unknown

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors (TH-CR-410)

Gastrointestinal Stromal Tumors | Advanced Renal Cell Carcinoma | Pancreatic Neuroendocrine Tumors

United States
Threshold Pharmaceuticals

Completed

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Pancreatic Cancer | Non-Small Cell Lung Cancer | Prostate Cancer

United States
Threshold Pharmaceuticals
Sarcoma Alliance for Research through Collaboration (SARC)

Completed

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, France, Canada, Spain, Germany, Belgium, Poland, Austria, Denmark, Hungary, Israel, Italy, Russian Federation
Grupo Espanol de Tumores Neuroendocrinos
Pfizer; Threshold Pharmaceuticals

Completed

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Pancreatic Neoplasms | Neuroendocrine Tumors

Spain
The University of Texas Health Science Center at...

Completed

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

HIGH GRADE GLIOMA

United States
Merrimack Pharmaceuticals

Unknown

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Breast Cancer

United States
Pfizer

Terminated

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Non-small Cell Lung Cancer | Urothelial Cancer

Spain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
Children's Specialized Hospital
University of Medicine and Dentistry of New Jersey

Completed

The Effect of FES on Children With Spinal Cord Injury

Spinal Cord Injury
Queensland Centre for Gynaecological Cancer
The University of Queensland

Recruiting

Sentinel Node Biopsy in Endometrial Cancer (ENDO-3)

Surgery | Sentinel Lymph Node | Endometrial Cancer Stage I

Australia, United States, Brazil, Singapore, India
PharmAbcine
Merck Sharp & Dohme LLC; Novotech (Australia) Pty Limited

Not yet recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01)

Advanced or Metastatic Solid Tumors

Australia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Threshold Pharmaceuticals

Completed

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Kidney Cancer | Liver Cancer

United States
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Terminated

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

Japan
The University of Texas Health Science Center at...

Completed

TH-302 in Combination With Bevacizumab for Glioblastoma

Glioblastoma

United States
4SC AG

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)

Malignant Melanoma

Germany, Italy
Maastricht Radiation Oncology
Threshold Pharmaceuticals; Zuyderland Medical Centre

Withdrawn

Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.

Esophageal Cancer
AHS Cancer Control Alberta
Alberta Cancer Foundation

Unknown

Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus)

SCCHN

Canada
Guangzhou University of Traditional Chinese Medicine
Akeso Pharmaceuticals, Inc.

Recruiting

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Non-small Cell Lung Cancer

China
Immune-Onc Therapeutics

Completed

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
University Hospital, Antwerp
Eli Lilly and Company; Universiteit Antwerpen

Completed

Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (PACCORA)

Non-Small Cell Lung Cancer

Belgium
Shanghai Zhongshan Hospital

Not yet recruiting

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer (WUKONG-9)

NSCLC
Shen Lin

Unknown

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Colorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2

China
Peking Union Medical College

Not yet recruiting

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Salivary Gland Cancer
Aurora Health Care

Recruiting

BurstDR Stimulation for Painful Diabetic Neuropathy

Painful Diabetic Neuropathy

United States
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Akeso

Not yet recruiting

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Sun Yat-sen University

Recruiting

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Second Affiliated Hospital of Nanchang University

Recruiting

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Immunotherapy | Tislelizumab | Pulmonary Pleomorphic Carcinoma

China
Aura Biosciences

Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder Cancer

United States
Shanghai Chest Hospital
Changhai Hospital; Ruijin Hospital

Unknown

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Lung Adenocarcinoma
West China Hospital
Sichuan Provincial People's Hospital; The First People's Hospital of Ziyang; Chengdu... and other collaborators

Not yet recruiting

The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Amanda Dandanell Juul

Recruiting

Navigation Endobronchial Ultrasound (NEBULA)

Lung Cancer

Denmark
Arvinas Androgen Receptor, Inc.

Active, not recruiting

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Metastatic

Canada, United States, France, United Kingdom
Peking Union Medical College Hospital

Recruiting

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
Changhai Hospital

Completed

Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer

Pancreatic Cancer

China
Threshold Pharmaceuticals

Completed

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)

Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

United States, Germany
AC Camargo Cancer Center

Recruiting

Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT) (BISQUIT)

Anal Cancer Squamous Cell

Brazil

Search clinical trials for: TH-302 combination with pemetrexed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations